Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.475
-0.065 (-4.22%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Chemomab Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2018
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2018
Selling, General & Admin
3.733.417.0811.566.03
Upgrade
Research & Development
5.8311.3318.3816.986.33
Upgrade
Operating Expenses
9.5714.7425.4628.5312.37
Upgrade
Operating Income
-9.57-14.74-25.46-28.53-12.37
Upgrade
Interest Expense
-----0.11
Upgrade
Interest & Investment Income
0.450.791.240.35-
Upgrade
Currency Exchange Gain (Loss)
0.130.01---
Upgrade
Pretax Income
-9-13.95-24.22-28.18-12.48
Upgrade
Income Tax Expense
----0.53-
Upgrade
Net Income
-9-13.95-24.22-27.65-12.48
Upgrade
Net Income to Common
-9-13.95-24.22-27.65-12.48
Upgrade
Shares Outstanding (Basic)
64333
Upgrade
Shares Outstanding (Diluted)
64333
Upgrade
Shares Change (YoY)
42.10%52.79%3.26%9.70%51.71%
Upgrade
EPS (Basic)
-1.41-3.11-8.25-9.72-4.81
Upgrade
EPS (Diluted)
-1.41-3.11-8.25-9.72-4.81
Upgrade
Free Cash Flow
-11.13-15.39-23.61-20.44-12.61
Upgrade
Free Cash Flow Per Share
-1.75-3.43-8.04-7.18-4.86
Upgrade
EBITDA
-9.5-14.69-25.39-28.48-12.33
Upgrade
D&A For EBITDA
0.070.050.070.060.03
Upgrade
EBIT
-9.57-14.74-25.46-28.53-12.37
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.